Even though I am no biotech analyst I know an undervalued share ,So the latest research report confirms our thoughts. PTR has or will have multiple trials underway in the short term in the US. Its price rise imho will occur in this difficult market, not from the local investors but from US investors.Already it is worth a fund managers attention at this low MC but the case will become more compelling as some of the trials start announcing good results and PTR may wait until they have further announcements
Iam fairly convinced that the next CR will occur in the US, after all, the trials are there, the personell are there, and the biotechs are better understood there. Roth is a small cap investment bank specialists and the latest conference March 10 was advertised as having 3000 attendees and it would not be to hard to get a list of investors who would see the value to invest, but naturally from our points of view and from PTR at a whole lot higher than the SP now.DR T Chew announced on 28 April to head the team is another building block adding more muscle to any future raising
PTX Price at posting:
8.6¢ Sentiment: Buy Disclosure: Held
